Expedition Therapeutics is a technology company.
Expedition Therapeutics has raised $170.0M across 1 funding round.
Expedition Therapeutics has raised $170.0M in total across 1 funding round.
Expedition Therapeutics has raised $170.0M in total across 1 funding round.
Expedition Therapeutics's investors include BoxOne Ventures, Sofinnova Investments.
Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases, with its lead candidate EXPD-101, a next-generation oral DPP1 inhibitor targeting neutrophilic inflammation in COPD and other neutrophil-driven conditions like bronchiectasis and neutrophilic asthma.[1][4] The company serves patients lacking disease-controlling treatments—nearly 70% of COPD cases—and aims to transform care by blocking neutrophil serine proteases (NSPs) that drive airway damage without depleting neutrophils or compromising immune function.[1][4] EXPD-101 demonstrated safety, target engagement, and once-daily pharmacokinetics in Phase 1 trials and is advancing to global Phase 2 in COPD, bolstered by a $165 million oversubscribed Series A in 2025 co-led by Sofinnova Investments and Novo Holdings.[4][5]
Expedition Therapeutics was founded around 2025 and is based in San Francisco, led by Yi Larson as Founder and CEO, alongside a seasoned team of biotech executives, scientists, and clinicians experienced in respiratory therapeutics, drug development, and commercialization.[1][2][4] The company emerged from strategic in-licensing, acquiring exclusive worldwide rights (excluding mainland China, Hong Kong, and Macau) to EXPD-101 from Fosun Pharma in August 2025, building on Fosun's ongoing Phase 2 bronchiectasis study in China.[4][5] Early traction includes Phase 1 success and substantial funding from investors like Venrock Healthcare Capital Partners, BVF Partners, Forbion, Dawn Biopharma (KKR), Adage, Balyasny, Logos Capital, and Sanofi Ventures, positioning it for rapid global advancement.[4]
(Note: One profile lists a focus on cancer therapies, but primary sources confirm respiratory and inflammatory diseases.[2])
Expedition rides the wave of precision respiratory medicine, targeting unmet needs in COPD—affecting millions with no disease-modifying options—amid rising demand for neutrophil-focused therapies in inflammatory diseases.[1][4] Timing aligns with China's biotech boom, enabling cost-effective in-licensing of advanced assets like EXPD-101, while global Phase 2 trials capitalize on post-pandemic focus on lung health.[5] Market forces favor it: aging populations drive COPD prevalence, and investor enthusiasm (e.g., oversubscribed Series A) reflects biotech's shift toward high-impact, mechanism-driven drugs over broad immunosuppressants.[4] Expedition influences the ecosystem by bridging U.S. development with Asian innovation, potentially setting standards for cross-border biotech partnerships.[4][5]
Expedition is primed for Phase 2 readout in COPD and bronchiectasis, with expansion into additional indications and potential milestones triggering up to $645M in Fosun payments.[4][5] Trends like AI-enhanced drug design and covalent chemistry in adjacent biotechs could accelerate its pipeline, though it differentiates via validated clinical data.[3] Its influence may grow as a leader in neutrophilic inflammation, delivering first/best-in-class therapies that redefine COPD standards—transforming patient care from symptom management to disease control, as promised from inception.[1]
Expedition Therapeutics has raised $170.0M across 1 funding round. Most recently, it raised $170.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $170.0M Series A | BoxOne Ventures, Sofinnova Investments |